MAPT and Alzheimer disease: Our findings support a “two‐hit model” to explain the pathological manifestations associated with AD where both aging‐ and Tau/Synuclein‐ driven metabolic reprogramming events cooperate with each other, and targeting both could be a potent therapeutic strategy.